Provided is a method for producing a β-lactam compound, the method comprising: introducing an aqueous dispersion liquid (i) of a β-lactam compound (a) having an amino group, an aqueous solution (ii) of a basic compound and an organic solution (iii) of a compound having an activated carboxyl group into different flow paths to cause the liquids to flow through the flow paths; dissolving the β-lactam compound (a) during flow of a mixed liquid of the liquid (i) and the liquid (ii) to obtain an aqueous solution (M1); and causing the β-lactam compound (a) and the compound having an activated carboxyl group to react with each other during flow of a mixed liquid (M2) of the aqueous solution (M1) and the liquid (iii), thereby obtaining a β-lactam compound (b) in which an amide bond is formed.
A61K 31/43 - Composés contenant des systèmes cycliques thia-4 aza-1 bicyclo [3.2.0] heptane, c.-à-d. composés contenant un système cyclique de formule , p. ex. pénicillines, pénèmes
The present invention provides a therapeutic agent for novel coronavirus infection comprising 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof as an active ingredient, which is administered to novel coronavirus infection patients testing negative for either one or both of IgG antibody against novel coronavirus and IgA antibody against novel coronavirus.
Severe fever with thrombocytopenia syndrome virus infection can be treated by administering to a severe fever with thrombocytopenia syndrome virus infection patient who is 70 years of age or older and who does not present sepsis as a complication at the start of treatment a pharmaceutical composition containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof as an active ingredient.
This agent for treating coronavirus infectious diseases caused by mutant viruses of SARS-COV-2 contains, as an active ingredient, 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof.
The present invention makes it possible to treat a coronavirus infection by administering a pharmaceutical composition containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof as an active ingredient to a patient infected with the coronavirus who has an aggravating risk factor and is in an early stage of the disease.
A pharmaceutical composition comprising Components (1) and (2):
(1) 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof; and
(2) a specific amine.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A pharmaceutical composition comprising Components (1) and (2):
(1) 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof; and
(2) a compound having a partial structure containing two heteroatoms separated by at least two carbon atoms, or a sulfite thereof.
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
8.
MEDICINE INFORMATION REMOTE SHARING SYSTEM AND MEDICINE INFORMATION REMOTE SHARING METHOD
Provided are a medicine information remote sharing system and a medicine information remote sharing method, whereby it becomes possible to improve the reliability of the remote sharing of the results of identification of a single-dose-packaged medicine and to make the management of the medicine easy. In a medicine identification apparatus, the drug types of medicines that are single-dose-packaged in a packaging bag in accordance with formulation information are identified, and a list of captured images and master images for the medicines having the drug types that are the results of the identification with respect to the individual packaging bags is generated in which a medicine is indicated as "unknown" when the drug type of the medicine is unknown. A server records facility information of the medicine identification apparatus, formulation information, captured images of the medicines which include the captured images and the list, and the results of the identification in a database. The information recorded in the database is accessible by a terminal device that can communicate with the server.
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
Provided are a drug and a method which suppress progress of tauopathy such as Alzheimer's disease. 1-(3-(2-(1-B enzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of reducing the amount of phosphorylated tau protein and an effect of reducing the amount of amyloid β protein in the brain parenchyma, and thus is effective as an agent for preventing or treating tauopathy. Tauopathy can be prevented or treated by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
10.
OBJECT IDENTIFICATION DEVICE, OBJECT IDENTIFICATION METHOD, AND PROGRAM
Provided are an object identification device, an object identification method, and a program that allow for identification of the types of individual objects using an image containing a plurality of objects that can include both a type-identifiable object and a type-unidentifiable object. This object identification device comprises: a detector that detects objects from an image containing a plurality of objects on an object-by-object basis; an identifier that estimates, with respect to a type-identifiable object among the objects detected by the detector for which the type of object can be identified from the image, the type of the object from the image, and that estimates, with respect to a type-unidentifiable object for which identification of the type of object is difficult but that allows for identification of a group to which the object belongs, the group to which the object belongs from the image; and a processing unit that performs group-specific processing that leads to identification of the type with respect to the object that has been estimated as a group by the identifier.
A61J 3/06 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration la forme de pilules, tablettes ou pastilles
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
11.
CORONAVIRUS INFECTION THERAPEUTIC AGENT FORMED THROUGH COMBINATION OF PYRAZINE DERIVATIVE AND ANOTHER CORONAVIRUS INFECTION THERAPEUTIC DRUG
An object of the present invention is to provide a novel combination of substances showing effects against coronavirus. The present invention provides a therapeutic agent for coronavirus infection comprising a combination of a pyrazine derivative or a salt thereof and another therapeutic agent for coronavirus infection.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
12.
THERAPEUTIC AGENT FOR AN RNA VIRUS INFECTION COMPRISING A COMBINATION OF A PYRAZINE DERIVATIVE AND A THIOPURINE DERIVATIVE
The present invention addresses the problem of providing a therapeutic agent for RNA viral infection that includes a novel combination of a pyrazine derivative and a specific compound, the novel combination exhibiting an effect against the RNA virus. The present invention also addresses the problem of providing a therapeutic agent for RNA viral infection that includes a combination of a pyrazine derivative and a specific compound, the combination being capable of simultaneously enhancing anti-virus activities against multiple RNA viruses. The present invention provides a therapeutic agent for RNA viral infection obtained by combining a pyrazine derivative or a salt thereof and a thiopurine derivative.
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
Coronavirus infection can be treated by administering a pharmaceutical composition comprising 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof as an active ingredient to coronavirus infection patient with non-serious pneumonia.
The present invention provides a therapeutic agent for COVID-19 administered to COVID-19 patients negative for IgG antibodies against SARS-CoV-2 and/or IgA antibodies against SARS-CoV-2, the therapeutic agent containing, as an active ingredient, 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof.
This agent for treating coronavirus infectious diseases caused by mutant viruses of SARS-CoV-2 contains, as an active ingredient, 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof.
The present invention makes it possible to treat a coronavirus infection by administering a pharmaceutical composition containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof as an active ingredient to a patient infected with the coronavirus who has an aggravating risk factor and is in an early stage of the disease.
A61P 31/14 - Antiviraux pour le traitement des virus ARN
17.
DRUG IDENTIFICATION DEVICE, DRUG IDENTIFICATION METHOD AND PROGRAM, DRUG IDENTIFICATION SYSTEM, DRUG LOADING PLATFORM, ILLUMINATION DEVICE, IMAGING ASSISTANCE DEVICE, LEARNED MODEL, AND LEARNING DEVICE
Provided are a drug identification device enabling highly accurate, easy, and highly usable identification of an engraved and/or printed drug, a drug identification method and program, a drug identification system, a drug loading platform, an illumination device, an imaging assistance device, a learned model, and learning device. A region of an engraved and/or printed drug to be identified is detected from a captured image including the drug to be identified, the region of the drug to be identified is processed to acquire an engraved/printed mark extraction image in which an engraved and/or printed mark of the drug to be identified is extracted, the engraved/printed mark extraction image is input to infer the drug type of the drug to be identified, and a drug type candidate for the drug to be identified is acquired.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
A pharmaceutical composition containing components (1) and (2): (1) a 6-fluoro-3-hydroxy-2-pyrazine carboxamide or a salt thereof; and (2) a prescribed amine.
A pharmaceutical composition containing components (1) and (2): (1) a 6-fluoro-3-hydroxy-2-pyrazine carboxamide or a salt thereof; and (2) a sulfite or a compound having a partial structure including two heteroatoms separated by at least two carbon atoms.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
Therapeutic agent for RNA viral infection comprising a combination of pyrazine derivative and compound which increases amount of pyrazine derivative ribose triphosphate in cell
It is an object of the present invention to provide a therapeutic agent for RNA viral infection, comprising a novel combination of a pyrazine derivative and a specific compound, which exhibits effects against an RNA virus, and also to provide a therapeutic agent for RNA viral infection, comprising a combination of a pyrazine derivative and a specific compound, which is capable of simultaneously reinforcing antiviral activities against a plurality of RNA viruses. According to the present invention, provided is a therapeutic agent for RNA viral infection, which comprises a combination of a pyrazine derivative or a salt thereof and a compound which increases the amount of a pyrazine derivative ribose triphosphate in a cell.
Provided are a drug identification system and drug identification method that improve readability of a drug display and make it possible to acquire ample information pertaining to identification of a drug based on display information. The present invention is provided with: a first lighting device (80) that is disposed on a first surface side of a drug (12) and illuminates the drug from the first surface side; a first imaging device (72) that is disposed on a second surface side opposite from the first surface of the drug, and images the drug from the second surface side; and at least one processor. The processor acquires, from the first imaging device, a first transmitted light image of the drug from when the drug was irradiated with illumination light from the first lighting device, acquires second display information of the drug, said information being displayed on the second surface of the drug, from the first transmitted light image, and identifies the drug on the basis of the acquired display information.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
22.
DRUG LIST DISPLAY METHOD AND PROGRAM, AND DRUG LIST
Provided are a drug list display method and program for displaying a photographed drug and a confirmed drug so as to be comparable, and a drug list. A drug information display step for acquiring a plurality of first cutout images in which regions in which drugs are displayed are each cut out from a first image in which the plurality of drugs are photographed from one side, the plurality of first cutout images are listed and displayed in a first region of a display in a fixed order so that each can be designated, and a plurality of correct drug information items, each confirmed by a user in relation to the plurality of first cutout images, are listed and displayed in a second region of the display that differs from the first region, wherein corresponding first cutout images and confirmed correct drug information items are associated and displayed.
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
23.
PHARMACEUTICAL PRODUCT INFORMATION TRANSFER SYSTEM, PHARMACEUTICAL PRODUCT INFORMATION TRANSFER METHOD, PHARMACEUTICAL PRODUCT IDENTIFICATION SYSTEM, MEDICAL INFORMATION SYSTEM, AND PROGRAM
Provided are a pharmaceutical product information transfer system, a pharmaceutical product information transfer method, a pharmaceutical product identification system, a medical information system, and a program that enable inputting of the result of identification of a pharmaceutical product into a hospital information system such as an electronic medical record at low cost, and enable correct inputting of the name of an identified pharmaceutical product. This pharmaceutical product information transfer system generates a first identification code by converting, into an identification code, text information of the name of an identified pharmaceutical product, and outputs information in which a first character display indicating the pharmaceutical product name and a code display of the first identification code are displayed side by side, using an output device. By reading the first identification code using an identification code reading device, the medical information system is allowed to acquire the text information of the name of the pharmaceutical product.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
24.
ENGRAVED MARK IDENTIFICATION DEVICE, ENGRAVED MARK IDENTIFICATION METHOD, AND DRUG IDENTIFICATION DEVICE
Provided are: an engraved mark identification device that identifies, from captured images, in a short time, illumination directions of a light source at the time of capturing the images; an engraved mark identification method; and a drug identification device. The present invention is provided with: a light source that emits illumination light to a to-be-imaged object having an engraved mark on the surface thereof, by switching a plurality of illumination directions; a camera for capturing an image of the to-be-imaged object; and a reflection member that reflects the illumination light and that is disposed such that a plurality of reflection regions respectively corresponding to the plurality of illumination directions are included, together with the to-be-imaged object, in image regions captured by the camera. The present invention specifies, on the basis of colors of the reflection regions included in a plurality of images in which the to-be-imaged object is imaged by the camera, the illumination directions of the light source at the time of capturing the images, and identifies the engraved mark from the plurality of images and the respective specified illumination directions.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
G06T 7/70 - Détermination de la position ou de l'orientation des objets ou des caméras
25.
THERAPEUTIC AGENT FOR RNA VIRAL INFECTION OBTAINED BY COMBINING PYRAZINE DERIVATIVE AND THIOPURINE DERIVATIVE
The present invention addresses the problem of providing a therapeutic agent for RNA viral infection that includes a novel combination of a pyrazine derivative and a specific compound, the novel combination exhibiting an effect against the RNA virus. The present invention also addresses the problem of providing a therapeutic agent for RNA viral infection that includes a combination of a pyrazine derivative and a specific compound, the combination being capable of simultaneously enhancing anti-virus activities against multiple RNA viruses. The present invention provides a therapeutic agent for RNA viral infection obtained by combining a pyrazine derivative or a salt thereof and a thiopurine derivative.
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07D 241/24 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
26.
HIGH-PURITY N-(5-METHOXY-2-PHENOXYPHENYL)METHANESULFONAMIDE AND METHOD FOR PRODUCING SAME
The present invention addresses the problem of providing N-(5-methoxy-2-phenoxyphenyl)methanesulfonamide with a reduced amount of impurities; and a method for producing the same. According to the present invention, provided are: N-(5-methoxy-2-phenoxyphenyl)methanesulfonamide which is an iguratimod intermediate and which has an extremely low content of impurities; and a method for producing the same. By using N-(5-methoxy-2-phenoxyphenyl)methanesulfonamide with an extremely low content of impurities, it is possible to produce iguratimod with an extremely low content of impurities.
C07C 303/38 - Préparation d'esters ou d'amides d'acides sulfuriquesPréparation d'acides sulfoniques ou de leurs esters, halogénures, anhydrides ou amides d'amides d'acides sulfoniques par réaction d'ammoniac ou d'amines avec des acides sulfoniques ou avec leurs esters, leurs anhydrides ou leurs halogénures
C07C 311/08 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone acycliques d'un squelette carboné acyclique saturé ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
27.
CORONAVIRUS INFECTION THERAPEUTIC AGENT FORMED THROUGH COMBINATION OF PYRAZINE DERIVATIVE AND ANOTHER CORONAVIRUS INFECTION THERAPEUTIC DRUG
A coronavirus infection therapeutic agent comprising a combination of a pyrazine derivative or a salt thereof and another coronavirus infection therapeutic drug.
A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
A61K 31/138 - Aryloxyalkylamines, p. ex. propranolol, tamoxifène, phénoxybenzamine
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/351 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle non condensés avec un autre cycle
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
A61K 31/366 - Lactones ayant des cycles à six chaînons, p. ex. delta-lactones
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p. ex. carbazole
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
A61K 31/4706 - 4-Aminoquinoléines8-Aminoquinoléines, p. ex. chloroquine, primaquine
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
A61K 31/5365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
A61K 31/59 - Composés contenant le système cyclique du 9,10-séco-cyclopenta[a]hydrophénanthrène
A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
A61K 31/662 - Acides du phosphore ou leurs esters ayant des liaisons P-C, p. ex. foscarnet, trichlorfon
A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
Coronavirus infection can be treated by administering a pharmaceutical composition comprising 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof as an active ingredient to coronavirus infection patient with non-serious pneumonia.
A coronavirus infection can be treated by administering a pharmaceutical composition containing 6-fluoro-3-hydrox-2-pyrradine carboxamide or a salt thereof, as an active ingredient, to a coronavirus infection patient with non-severe pneumonia.
ABCabcc,…) for the respective training images; and storage control for storing each pair of the generated training image and the correct answer data in the memory (28) as training data.
Provided is a drug identification device that, on the basis of the actual travel distance of a packaging bag, determines a boundary candidate near a location as the boundary. The drug identification device comprises: an insertion port for inserting continuous packaging bags having drugs separated into individual packages by a packaging machine; a drive device that transports the packaging bags inserted from the insertion port along a transport path to an imaging area; an imaging element that captures an image of a packaging bag including a drug, in the imaging area; a processor that identifies the drug on the basis of the captured image; and an optical flow sensor disposed upon the transport path. The processor: drives the drive device so that an upstream boundary for the packaging bag is moved downstream by a set distance; calculates the travel distance for the packaging bag from information obtained from the optical flow sensor; and determines, as a downstream boundary, a downstream boundary candidate positioned close to the travel distance, in the image after travel.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
32.
DRUG IDENTIFICATION DEVICE AND DRUG IDENTIFICATION METHOD
Provided are a drug identification device whereby overlap between drugs in a packaging bag can be dispersed, and a drug identification method. A drug identification device having a charging port for charging of a packaging bag in which a drug is packaged, a conveyance path for conveying a packaging bag charged from the charging port, an imaging element for capturing an image of the drug on the conveyance path, a processor for identifying the drug on the basis of the image of the drug captured by the imaging element, an accommodating case for accommodating a packaging bag positioned upstream from the charging port, and a vibration device for causing the accommodating case to vibrate.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
B65B 1/30 - Dispositifs ou procédés pour régler ou déterminer la quantité ou la qualité du matériau fourni ou chargé
B65B 57/10 - Dispositifs de commande automatique, de vérification, d'alarme ou de sécurité sensibles à l'absence, à la présence, à l'alimentation anormale ou au mauvais positionnement des objets ou matériaux à emballer
33.
OBJECT RECOGNITION APPARATUS, METHOD, PROGRAM, AND LEARNING DATA
Provided are an object recognition apparatus, a method, a program, and learning data that can recognize respective target objects with high accuracy from a photographed image in which a plurality of target objects are photographed. An image acquisition unit (22) of an object recognition apparatus (20-1) acquires a photographed image in which two or more agents of a plurality of target objects (agents) are being in point or line contact with each other. A first recognizer (30) inputs the photographed image and generates an edge image of the photographed image showing only a portion being in point or line contact. A second recognizer (32) inputs the photographed image and the edge image, and respectively recognizes the plurality of agents from the photographed image to output a recognized result. The second recognizer (32) inputs information (edge image showing only portions being in point or line contact) useful for area reparation of the respective agents in addition to the photographed image, and therefore, even when areas of the two or more agents of the plurality of agents are being in point or line contact, the areas of the plurality of agents can be recognized by being separated with high accuracy.
Provided are an image processing device and method that are capable of improving drug visibility. A captured image of drugs is acquired, the drugs are detected from the acquired image, and images of the detected drugs are cut out to generate individual drug images. The quality of the visibility of the generated individual drug image is assessed, and individual drug images with poor visibility are subjected to a visibility-improving process before being displayed on a display device.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
Required are: a compound having high affinity for an emopamil binding protein; and a method for activating or inhibiting the emopamil binding protein, using such a compound. According to the present invention, provided is an emopamil binding protein binding agent comprising an alkyl ether derivative represented by the following formula [1] or a salt thereof:
3 represents an optionally protected hydroxyl group, etc.; and m and n, which are the same or different, each represent an integer of 1 to 6.
C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
36.
COMPOSITION AND METHOD FOR TREATING CANDIDA AURIS INFECTION
Candida auris infection in a subject is treated with 4-{3-[4-(3-{4-[amino(imino)methyl]phenoxy}propyl)-1-piperidinyl]propoxy}benzamidine (T-2307) or a pharmaceutically acceptable salt thereof.
An object of the present invention is to provide a drug and a method which suppress progress of disease in which the amount of amyloid β protein in the brain is increased, such as Alzheimer's disease. 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of reducing the amount of amyloid β protein in the brain parenchyma, and thus is effective as an agent for reducing the amount of amyloid β protein in the brain. Disease in which the amount of amyloid β protein in the brain is increased, such as Alzheimer's disease, can be prevented or treated by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
38.
Object collating device and object collating method
It is an object of the present invention to provide an object collating device and an object collating method that enable matching of images of a dividable medical article with desirable accuracy and easy confirmation of matching results. In the object collating device according to the first aspect, when the object is determined to be divided, the first image for matching is collated with the image for matching (the second matching image) for the objects in the undivided state, so that the region to be matched is not narrowed, and matching of the images of the dividable medical article is achieved with desirable accuracy. In addition, since the first and second display processing is performed on the images for display determined to contain the objects of the same type, matching results can easily be confirmed.
G06T 7/30 - Détermination des paramètres de transformation pour l'alignement des images, c.-à-d. recalage des images
G06K 9/62 - Méthodes ou dispositions pour la reconnaissance utilisant des moyens électroniques
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
G16H 20/13 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients delivrés par des distributeurs
A61J 1/03 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques pour pilules ou comprimés
A61J 7/00 - Dispositifs pour administrer les médicaments par voie buccale, p. ex. cuillèresDispositifs pour compter les pilulesDispositions pour l'indication ou le rappel du moment où l'on doit prendre des médicaments
G06V 10/44 - Extraction de caractéristiques locales par analyse des parties du motif, p. ex. par détection d’arêtes, de contours, de boucles, d’angles, de barres ou d’intersectionsAnalyse de connectivité, p. ex. de composantes connectées
G06V 10/75 - Organisation de procédés de l’appariement, p. ex. comparaisons simultanées ou séquentielles des caractéristiques d’images ou de vidéosApproches-approximative-fine, p. ex. approches multi-échellesAppariement de motifs d’image ou de vidéoMesures de proximité dans les espaces de caractéristiques utilisant l’analyse de contexteSélection des dictionnaires
Provided are a medicine collation device, a medicine collation system, a medicine management method, and a program which can collect medicine images that are candidates of a master image. The present invention is provided with: a medicine image acquisition unit (60) which acquires a medicine image captured of a medicine to be collated; a first master image storage unit (64) which stores a master image of the medicine; a collation unit (62) which collates the medicine image with the master image; an association unit (66) which associates identification information about the medicine image with the medicine image collated by using the collation unit; and a transmission unit (68) which transmits, to the outside, the medicine image and the identification information associated in the association unit.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
A61J 3/06 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration la forme de pilules, tablettes ou pastilles
Provided are a conveyor whereby a break in a portion packaging bag can be detected, and a medicine inspection support system. The conveyor conveys a portion packaging bag to an inspection machine, the portion packaging bag being sectioned by a heat-sealed part and perforations for each package by a portion packaging machine and being continuously discharged in a vertical orientation from the portion packaging machine, and the conveyor comprises an orientation changing device for changing the orientation of the portion packaging bag from a vertical orientation to a horizontal orientation, and a detection device for detecting a break in the portion packaging bag.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
This method for producing a freeze-dried formulation including an amorphous form of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide sodium salt is useful as a method for producing a freeze-dried formulation having uniform quality.
Provided are an image processing device, a portable terminal, an image processing method, and a program with which it is possible to easily acquire an image in which the marking or printing added to an object to be recognized is emphasized. A smartphone (100) comprises: a recognizer (101B) that has been trained by machine learning using a learning dataset for learning for a plurality of different medicines that have been marked or printed on, a set being formed by a first medicine image in which the marking or printing is not emphasized and a second medicine image in which the marking or printing is emphasized; a camera unit (141) functioning as an image input unit for inputting, to the recognizer (101B), a third image which is an image of a discretionary medicine that has been marked or printed on and in which the marking or printing is not emphasized; and an image output unit for outputting the recognition result obtained from the recognizer (101B) to a display unit (120) when the third image has been inputted to the recognizer (101B).
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
One embodiment of the present invention provides an identification assistance system, identification assistance client, identification assistance server and identification assistance method with which it is possible for a user to accurately identify a drug. The identification assistance system according to a first aspect of the present invention comprises: an image acquisition unit which acquires an image of a drug; a text generation unit which, character by character, extracts a character string contained in the image and generates first text indicating the character string; a text amendment unit which amends the first text on the basis of an expression used for drug identification and generates second text; a drug master in which identification information indicating a drug code and/or name and character information indicating characters attached to the drug are stored as text; a comparison unit which compares the second text with the drug master to acquire identification information for a candidate drug, which is a candidate for the drug indicated by the second text; and an output unit which outputs the identification information for the candidate drug.
G06K 9/66 - Méthodes ou dispositions pour la reconnaissance utilisant des moyens électroniques utilisant des comparaisons ou corrélations simultanées de signaux images avec une pluralité de références, p.ex. matrice de résistances avec des références réglables par une méthode adaptative, p.ex. en s'instruisant
G06K 9/72 - Méthodes ou dispositions pour la reconnaissance utilisant des moyens électroniques utilisant une analyse de contexte basée sur l'identité provisoire attribuée à une série de formes successives, p.ex. d'un mot
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
44.
DRUG IDENTIFICATION DEVICE, DRUG IDENTIFICATION METHOD, AND PROGRAM
Provided are a drug identification device, a drug identification method, and a program with which it is possible for efficient identification to be carried out accurately, even when identifying drugs including drugs that are similar to one another. A drug identification device (2) is provided with: a drug database (20A); an image input unit (10A) into which a target image is input; a drug region extracting unit (10B) which extracts from the target image a drug region in which a drug appears; a registered image acquiring unit (10C) which acquires a first registered image and a second registered image; a first recognizing unit (10D) which performs similarity recognition between the drug region and the corresponding first registered image; a second recognizing unit (10E) which performs similarity recognition with the second registered image, for a drug region that has been recognized by the first recognizing unit as being similar to the first registered image; and a drug identifying unit (10F) which identifies whether the drug is a first drug on the basis of the recognition results from the first recognizing unit and the second recognizing unit.
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
45.
IMAGE GENERATION DEVICE, MEDICINE IDENTIFICATION DEVICE, MEDICINE DISPLAY DEVICE, IMAGE GENERATION METHOD, AND PROGRAM
Provided are an image generation device, a medicine identification device, a medicine display device, an image generation method, and a program capable of acquiring a medicine image on which a highlighting process has been performed efficiently. An image generation device (2) is provided with: an illumination unit (10) in which light-emitting parts simultaneously illuminate the surface of a medicine from the respective different irradiation directions; an imaging unit (12) that acquires a plurality of first images of the medicine corresponding to the respective wavelength bands from an imaging element; an image generation unit (16) that, on the basis of the plurality of first images acquired by the imaging unit (12), generates a second image obtained by performing a highlighting process for highlighting marking or print provided to the surface of the medicine; and a process control unit (18) that, when at least two of the respective output values of the plurality of first images are not less than a threshold value, causes the image generation unit (16) to generate the second image, and that, when less than two of the respective output values of the plurality of first images are not less than the threshold value, performs control such that the image generation unit (16) does not generate the second image.
G01N 21/85 - Analyse des fluides ou solides granulés en mouvement
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
G06T 1/00 - Traitement de données d'image, d'application générale
H04N 9/07 - Générateurs de signaux d'image avec une seule tête de lecture
The purpose of the present invention is to provide an identification assistance system, an identification assistance client, and an identification assistance method which make it possible for a user to accurately and easily identify a drug. Another purpose of the present invention is to provide an identification assistance server to be used in drug identification. According to one embodiment of the identification assistance system of the present invention, a first text which is the result of voice recognition is corrected, so voice recognition mistakes can be corrected. In addition, a drug search dictionary which has been caused to learn expressions used in drug classification is referenced to correct the first text, so an expression unique to drug classification can be taken into consideration. A user can execute a search by speaking not only a drug code and/or name, but also external appearance information. A search can be performed using external appearance information even if the code or the name is unknown.
G10L 15/22 - Procédures utilisées pendant le processus de reconnaissance de la parole, p. ex. dialogue homme-machine
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
47.
Medicine verification device and medicine verification method
In the present invention, an image of a verification target medicine disposed on an arrangement unit is captured, prescription condition information indicating a prescription condition is acquired, an external force application unit is caused to execute an external force applying operation of applying an external force to the medicine disposed on the arrangement unit to move the medicine when an operation execution condition is satisfied, wherein the operation execution condition includes at least one of: a first operation execution condition that the number of the verification target medicines appearing in the image differs from the quantity of the medicines specified from the prescription condition information; and a second operation execution condition that a shape of the verification target medicine appearing in the image differs from a shape corresponding to a type of the medicine specified from the prescription condition information.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
G16H 20/13 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients delivrés par des distributeurs
H04N 5/247 - Disposition des caméras de télévision
G06K 9/62 - Méthodes ou dispositions pour la reconnaissance utilisant des moyens électroniques
A purpose of the present invention is to provide a medical information registration support device, a medical information registration support method, and a program, wherein a user can easily register medical information. A medical information registration support device according to a first embodiment of the present invention comprises: an input reception unit that receives input of medical information; an evaluation unit that evaluates whether the received medical information and registration information match; a candidate generation unit that, when the received medical information and the registration information do not match, uses a learned model to generate a candidate for registration information corresponding to the received medical information, said learned model being structured through machine learning and being a learned model that standardizes inputted medical information according to the type of medical information and outputs the result; and a registration unit that associates, with the received medical information, medical information selected from the candidate or medical information in which the candidate has been corrected, and registers the result as registration information.
G16H 15/00 - TIC spécialement adaptées aux rapports médicaux, p. ex. leur création ou leur transmission
G16H 50/00 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies
Provided is a medicine management system capable of confirming a receipt status and a medication status of a delivered medicine even at a delivery source. The present invention comprises: a management server which manages the receipt status and the medication status of delivered medicine; a first terminal having a function of notifying the management server of information indicating receipt when the medicine is received; a second terminal having a function of notifying the management server of information indicating medication when medication is taken; and a third terminal having a function of acquiring information on the receipt status and the medication status of the medicine from the management server, and displaying the acquired information. The medicine includes a packaged medicine packaged on the basis of prescription information, and unique delivery identification information is given for each delivery. The delivery identification information is displayed on a delivered item that is to be delivered together with the medicine. Unique medicine identification information on the packaged medicine is given for each package and displayed on each of the sachets. The management server manages the medicine identification information in association with the delivery identification information and the information extracted from the prescription information. The first terminal reads the delivery identification information displayed on the delivery and notifies the management server of information indicating receipt. The second terminal reads the medicine identification information displayed on the sachet and notifies the management server of information indicating medication. The management server receives the notification of the information indicating the receipt from the first terminal to manage the receipt status of the medicine, and receives the notification of the information indicating the medication from the second terminal to manage the medication status of the medicine.
B65G 61/00 - Utilisation d'appareils de prise ou de transfert, ou de manipulateurs, pour empiler ou désempiler des objets, non prévus ailleurs
A61J 7/04 - Dispositions pour l'indication ou le rappel du moment où l'on doit prendre des médicaments, p. ex. distributeurs programmés
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
50.
MEDICAL DRUG VERIFICATION DEVICE, MEDICAL DRUG VERIFICATION METHOD, AND MEDICAL DRUG VERIFICATION SYSTEM
The purpose of the present invention is to provide a medical drug verification device, a medical drug verification method, and a medical drug verification system, which enable improving robustness in matching information on medical drugs. The medical drug verification device according to a first embodiment of the present invention is provided with: an exterior information acquisition unit which acquires exterior information of a medical drug; a matching unit which performs matching between verification target information based on the acquired exterior information and a standard information group, regarding medical drugs, stored in a memory; a display control unit which, on the basis of a degree of matching, causes a display device to display multiple candidates of standard information about a medical drug corresponding to the exterior information contained in the standard information group; a reception unit which receives a selection of standard information included in the multiple candidates; a reflection unit which causes the verification target information and/or exterior information corresponding to the selected standard information to be reflected in the stored standard information group, wherein the reflection unit performs reflection in the case when the degree of matching with regard to the selected standard information fails to fulfill a predetermined standard.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
51.
MEDICINE IDENTIFICATION SYSTEM, MEDICINE IDENTIFICATION DEVICE, MEDICINE IDENTIFICATION METHOD, AND PROGRAM
Provided are a medicine identification system whereby a medicine can be satisfactorily identified by a simple device in which a portable terminal provided with a camera is used, a medicine identification method, and a program. In a smartphone (100) having a camera on the same surface side as a display, a light emission region of the display is changed, the direction of illumination on a medicine (20) placed on a tray (10) having an indicator used to standardize the size and shape of a medicine is changed, and an image of the medicine (20) in a different illumination direction is captured by the camera. A medicine identification device standardizes the size and shape of a plurality of first images acquired by imaging, on the basis of indicators (14A-14D) in the first images, and extracts an image of each medicine region from the standardized plurality of first images. A second image is generated in which emphasis processing is applied for emphasizing a mark or printing applied to the medicine (20), on the basis of the extracted plurality of medicine region images, and the medicine is identified on the basis of the generated second image.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
An object of the present invention is to provide a drug which prevents progress of Alzheimer's disease and a method of preventing progress of Alzheimer's disease. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of suppressing brain atrophy and is useful as an agent for preventing or treating brain atrophy. Brain atrophy observed in aging or neurodegenerative diseases can be prevented or treated by administering 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
53.
THERAPEUTIC AGENT FOR RNA VIRAL INFECTION OBTAINED BY COMBINING PYRAZINE DERIVATIVE AND COMPOUND INCREASING AMOUNT OF PYRAZINE DERIVATIVE RIBOSE TRIPHOSPHATE BODIES IN CELL
The problem of the present invention is to provide a therapeutic agent for an RNA viral infection which comprises a novel combination of a pyrazine derivative and a specified compound and which is exhibits an effect against an RNA virus, and to provide a therapeutic agent for an RNA viral infection which comprises the combination of the pyrazine derivative and the specified compound and which can simultaneously potentiate antiviral activity against a plurality of RNA viruses. The present invention provides a therapeutic agent for an RNA viral infection obtained by combining a pyrazine derivative or a salt thereof, and a compound which increases the amount of pyrazine derivative ribose triphosphate bodies in a cell.
A medicine inspection device, an image processing device, an image processing method, and a program are provided that appropriately extract identification information even when the positional relationship between a printed character and an engraved mark added to a medicine is not constant. The above problem is solved by an image processing device that performs a process of enhancing a printed character portion of a medicine based on at least one image taken with a surface of the medicine being irradiated with light to generate a printed-character-enhanced image, performs a process of extracting only an engraved mark portion from a three-dimensional shape of the medicine based on at least three images taken with illumination directions of the light to the surface of the medicine different from each other to generate an engraved-mark-extracted image, and generates a difference image between the printed-character-enhanced image and the engraved-mark-extracted image.
G06K 9/62 - Méthodes ou dispositions pour la reconnaissance utilisant des moyens électroniques
G06T 7/586 - Récupération de la profondeur ou de la forme à partir de plusieurs images à partir de plusieurs sources de lumière, p. ex. stéréophotométrie
G16H 70/40 - TIC spécialement adaptées au maniement ou au traitement de références médicales concernant des médicaments, p. ex. leurs effets secondaires ou leur usage prévu
G06K 7/14 - Méthodes ou dispositions pour la lecture de supports d'enregistrement par radiation électromagnétique, p. ex. lecture optiqueMéthodes ou dispositions pour la lecture de supports d'enregistrement par radiation corpusculaire utilisant la lumière sans sélection des longueurs d'onde, p. ex. lecture de la lumière blanche réfléchie
G06V 10/145 - Éclairage spécialement adapté à la reconnaissance de formes, p. ex. utilisant des réseaux
G06V 10/75 - Organisation de procédés de l’appariement, p. ex. comparaisons simultanées ou séquentielles des caractéristiques d’images ou de vidéosApproches-approximative-fine, p. ex. approches multi-échellesAppariement de motifs d’image ou de vidéoMesures de proximité dans les espaces de caractéristiques utilisant l’analyse de contexteSélection des dictionnaires
55.
DRUG IDENTIFICATION DEVICE, DRUG IDENTIFICATION METHOD, AND DRUG IDENTIFICATION PROGRAM
Provided are a drug identification device, a drug identification method, and a drug identification program with which the amount of teaching data can be significantly reduced when identifying a drug by machine learning. The drug identification device is equipped with: an image acquisition unit for acquiring a plurality of images of a drug for which the illumination direction of light illuminating a surface of the drug differs; an image processing unit for generating drug images (27A, 27B) for which an enhancement process, in which markings applied to the drug are enhanced on the basis of the plurality of images, has been carried out on drug images (25A, 25B); a feature amount calculation unit for calculating a feature amount of the drug images (27A, 27B); and a deduction unit (40) for deducing, on the basis of the feature amounts of the drug images (27A, 27B), which registered drug a drug is closest to.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment of influenza infection; pharmaceutical preparations for the treatment of coronavirus infection; antiviral pharmaceuticals.
57.
Agent for preventing or treating Alzheimer's disease
An object of the present invention is to provide a drug which prevents progress of Alzheimer's disease and a method of preventing progress of Alzheimer's disease. Alzheimer's disease can be effectively prevented or treated by initiating administration of a pharmaceutical composition comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof as an active ingredient to a patient within a certain period from clinical diagnosis of Alzheimer's disease.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
58.
Agent for preventing or treating spinocerebellar ataxia
An object of the present invention is to provide an excellent drug for preventing or treating spinocerebellar ataxia. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of suppressing brain atrophy, especially cerebellar atrophy, and is useful as an agent for preventing or treating spinocerebellar ataxia. Cerebellar atrophy observed in spinocerebellar ataxia can be prevented or treated by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
59.
OBJECT COMPARISON DEVICE AND OBJECT COMPARISON METHOD
The objective of the present invention to provide an object comparison device and an object comparison method with which images of dividable medicinal goods can be matched with good precision and with which the matching result can be easily verified. When an object is determined to have been divided, the object comparison device according to a first aspect of the present invention compares a first image for matching to an image for matching of the object in a non-divided state (second image for matching), and thus is capable of matching images of dividable medicinal goods with excellent accuracy, without the matching target region becoming small. In addition, since first and second display processing are conducted for a display image determined to picture an object of the same type, the matching result can be confirmed readily.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
G01N 21/85 - Analyse des fluides ou solides granulés en mouvement
G01N 21/88 - Recherche de la présence de criques, de défauts ou de souillures
INFORMATION PROVISION SYSTEM, INFORMATION PROVISION SERVER, INFORMATION PROVISION METHOD, INFORMATION PROVISION SOFTWARE, AND CONVERSATION-TYPE SOFTWARE
Provided are an information provision system, an information provision server, an information provision method, information provision software, and conversation-type software, with which medical product information including detailed information of a medical product can be easily acquired and efficiently utilized by using a conversational agent terminal. A customer can converse with a conversational agent (an AI agent) through a conversational agent terminal (100), and the conversational agent terminal (100) receives product-identifying information on the basis of a conversation-type interface and transmits the received product-identifying information to a network (2) via an information provision server (10). Upon receiving the product-identifying information from the conversational agent terminal (100), the information provision server (10) reads the medical product information associated with the product-identifying information and delivers the medical product information via the conversational agent terminal (100) to software requiring the medical product information.
G16H 40/20 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion ou l’administration de ressources ou d’établissements de soins de santé, p. ex. pour la gestion du personnel hospitalier ou de salles d’opération
61.
CXCR4-BINDING COMPOUND OR SALT THEREOF, OR COMPLEX OF SAME AND METAL
Provided are: a CXCR4-binding compound having high accumulation in tumors that express CXCR4; and a treatment agent for diagnosis or therapy, etc., having the compound as an active ingredient. A compound represented by general formula (1) (the symbols in the formula are set forth in the description), a salt thereof, or a complex of the same and a metal.
C07K 7/54 - Peptides cycliques contenant au moins une liaison peptidique anormale comportant au moins une liaison peptidique anormale dans le cycle
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
An object of the present invention is to provide a pharmaceutical composition comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof at a high concentration, with a characteristic bitter taste masked, and a manufacturing method thereof. The present invention provides a pharmaceutical composition comprising fine granules having a core comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof, and a binder; and a polymer layer with which a surface of the core is coated, wherein the fine granules have a roundness of 0.8 or more and a content of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt thereof in the fine granules is 30 to 90% by mass.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
2O or less, wherein pH of a solution obtained when the solid pharmaceutical composition is dissolved or suspended in a 10 mmol/L KCl solution such that 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt thereof is 1 mg/mL or 8.96 mg/mL is 4.8 or less.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
Inventeur(s)
Makita, Keiko
Saeki, Kazunori
Tanaka, Tadashi
Fujino, Masataka
Natsume, Tohru
Furuya, Kentaro
Abrégé
It is an object of the present invention to provide an antitumor agent, which is further excellent as a treatment agent used in the prevention and/or therapy of tumor associated with a bromodomain, and also to provide a bromodomain inhibitor, which is useful as a treatment agent for diseases or states associated with a bromodomain.
An antitumor agent and a bromodomain inhibitor, comprising a compound represented by the following formula, have an excellent bromodomain inhibitory activity and are useful as treatment agents in the prevention and/or therapy of tumor associated with a bromodomain, and the like:
4 represents a halogen atom, etc.; and m represents an integer from 0 to 5.
Provided are: a drug determination device that is capable of accurately determining the type, etc. of a drug even when there is a difference in sharpness between a master image and a captured imaged of a drug to be determined; and a drug determination method. An image of the drug to be determined, which is packaged in a packaging material, is captured, the master image and the captured image of the drug to be determined are used to determine the type of the drug to be determined, and characteristic information indicating the optical characteristics of the packaging material in which the drug to be determined is packaged is acquired. If the optical characteristics indicated by the acquired characteristic information cause the sharpness of the captured image of the drug to be determined to be lower than the sharpness of the master image, correction processing for correcting the sharpness of the master image is executed, and the sharpness-corrected master image is used to determine the type of the drug to be determined.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
G01N 21/85 - Analyse des fluides ou solides granulés en mouvement
Provided are a drug determination device and a drug determination method, whereby a master image can be updated in consideration of an optical characteristic of a packaging material which affects visibility of an image. In the present invention, an image of a drug to be determined which is wrapped in a light-transmitting packaging material is captured, the type of the drug to be determined is determined using a master image and the captured image of the drug to be determined, and characteristic information indicating an optical characteristic which affects visibility of the captured image is acquired for the packaging material in which the drug to be determined is wrapped, the type of the drug to be determined having been determined to match the type of the drug appearing in the master image. When a determination is made that the type of the drug to be determined matches the type of the drug appearing in the master image, an assessment is made as to whether the optical characteristic indicated by the characteristic information acquired for the packaging material in which the drug to be determined is wrapped satisfies a standard, and when the optical characteristic satisfies the standard, update processing is executed for updating a registered master image to the image of the drug to be determined.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
G01N 21/85 - Analyse des fluides ou solides granulés en mouvement
Provided are a medicine assessment device and a method of detecting a boundary recess which are capable of appropriately detecting the position of a boundary recess provided in a boundary between packaging bags of a packaging bag continuous body. With regards to the detection of a boundary recess formed in a boundary position between packaging bags of a belt-like packaging bag continuous body constituted by a line of a plurality of packaging bags enveloping medicine, said detection involves projecting light onto the surface of the packaging bag continuous body at least at a portion thereof to be imaged which is where the boundary location would be located, and in this state, taking multiple images of the surface of the portion to be imaged under different imaging conditions, then, detecting the boundary recess in the imaged portion on the basis of the images taken under each imaging condition.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
Provided are a medicine determination device and a medicine determination method which are capable of appropriately determining whether it is necessary to move a medicine and of improving accuracy and speed of medicine determination. In this medicine determination device and this medicine determination method, a medicine to be determined is placed in a placement unit, an image of the medicine being determined placed in the placement unit is photographed, prescription condition information that indicates a prescription condition is obtained, and when a movement execution condition is satisfied, an external force application unit is caused to execute an external force application movement to move the medicine by applying an external force to the medicine placed in the placement unit. The movement execution condition includes at least one of a first movement execution condition for which the number of the medicines being determined in the image is different from the quantity of medicine specified by the prescription condition information, and a second movement execution condition for which the shape of the medicine being determined in the image is different from the shape corresponding to the type of medicine specified by the prescription condition information.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
Provided is a medication auditing support system capable of adjusting the difference in processing speed between a packaging machine and an auditing machine. This medication auditing support system 10 is provided with: a packaging machine 100 for packaging medication on the basis of prescription data and discharging sequential packaged pouches; a conveyance machine 200 for receiving the sequential packaged pouches 118 discharged from the packaging machine 100 and dispatching the sequential packaged pouches 118; an auditing machine 300 for receiving the sequential packaged pouches 118 dispatched from the conveyance machine 200 and auditing the medication packaged in the sequential packaged pouches 118 on the basis of the prescription data; and a controller for controlling the packaging machine 100, the conveyance machine 200, and the auditing machine 300. The conveyance machine 200 is provided with a turret mechanism 208 as a buffer part.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
This method for producing a freeze-dried formulation including an amorphous form of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide sodium salt is useful as a method for producing a freeze-dried formulation having uniform quality.
The purpose of the present invention is to provide a method for producing 6-bromo-3-hydroxy-2-pyrazinecarboxamide in which the content ratio of impurities is reduced. This production method includes a step of obtaining 6-bromo-3-hydroxy-2-pyrazinecarboxamide crystal having diffraction angles expressed in degrees 2θ of 5.5, 20.1, 23.7, 26.7, 27.5, and 28.1° and/or diffraction angles expressed in degrees 2θ of 7.1, 21.4, 25.2, 25.7, 27.1, and 28.8° in powder X-ray diffraction.
There are demands: for a compound having high affinity for the emopamil binding protein; and for a method for activating or inhibiting the emopamil binding protein by use of the compound. The present invention provides an emopamil binding protein binding agent characterized by containing: an alkyl ether derivative represented by general formula [1] "where R1and R21-61-6 alkyl group, an optionally-substituted aryl group, or the like, R3 represents an optionally-substituted hydroxyl group, or the like, and m and n are identical to or different from each other and each represent an integer of 1-6"; or a salt thereof.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie
A61P 27/12 - Agents ophtalmiques pour le traitement de la cataracte
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
73.
Method for producing 5-(bromomethyl)-1-benzothiophene
Provided is a method for industrially producing 5-(bromomethyl)-1-benzothiophene. The production method according to the present invention comprises: (1) a step for introducing 5-methyl-1-benzothiophene, a brominating agent, and a solvent into a reactor; (2) a step for emitting light having a wavelength range of 200-780 nm inside the reactor; and (3) a step for recovering 5-(bromomethyl)-1-benzothiophene from the reactor.
C07D 333/54 - Benzo [b] thiophènesBenzo [b] thiophènes hydrogénés avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone de l'hétérocycle
B01J 19/12 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage utilisant des radiations électromagnétiques
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations, namely, pharmaceutical agents affecting central nervous system, pharmaceutical agents affecting peripheral nervous system, pharmaceutical agents affecting sensory organs, antiallergic medicines, cardiovascular agents for medical purposes, agents affecting respiratory organs, pharmaceutical agents affecting digestive organs, hormones for medical purposes, oxytocics, antihemorrhoidal preparations, emmenagogues, urinary tract disinfectants, contraceptive preparations, pharmaceutical agents for epidermis, vitamin preparations for medical purposes, amino acid preparations for medical purposes, royal jelly for medical purposes, organotherapeutics, mineral preparations for medical purposes, medicinal alcohol, anticoagulants, blood substitute for human use, blood plasma, hemostatics for medical purposes, pharmaceutical agents affecting metabolism, cellular function activating agents, tumor suppressing agents, pharmaceutical agents for treating physically caused lesions, pharmaceutical agents for treating chemically caused disorders, antibiotic preparations, chemotherapeutics, antitoxic sera, antitoxins, vaccines, preparations for destroying parasites, diagnostic preparations for medical purposes, radio-isotope markers for therapeutic or diagnostic use, prescription synthetic narcotics, veterinary vaccines, anti-infective products for veterinary use, veterinary preparations for treatment of intestinal bacteria; preparations for destroying vermin, fungicides, herbicides; radioactive substances for medical purposes; reagent paper for medical purposes; oiled paper for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton, namely, absorbent cotton pants for incontinence; adhesive plasters for medical purposes; bandages for dressings; breast-nursing pads; cotton swabs for medical use; dietary supplements for humans; dietetic beverages adapted for medical purposes; dietetic food adapted for medical purposes; dietary supplements for animals
C07D 215/48 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
An object of the present invention is to provide an inspection support method and an inspection support device capable of easily inspecting packaged medicines. In accordance with the inspection support method and the inspection support device according to an aspect of the present invention, since images of packaged medicines and identification information items and quantities of medicines extracted from a prescription are displayed on a display device (display unit), a user can easily check whether or not the packaged medicines match those written in the prescription. Since master images are registered in a case where the determination of “whether or not identification information items and quantities of the packaged medicines match the identification information items and quantities which are extracted from the prescription and are displayed” is positive for all the medicines written in the prescription, it is possible to reduce a concern that inappropriate images will be registered as the master images. It is easy to align imaging conditions between the master images and collating target images, and it is possible to increase collation accuracy.
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
G06K 9/62 - Méthodes ou dispositions pour la reconnaissance utilisant des moyens électroniques
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
G16H 20/13 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients delivrés par des distributeurs
A tablet which comprises (1) 1-(3-(2-(1-benzothiophen-5- yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and (2) ethyl cellulose, said tablet having excellent elution properties and good moldability, remaining stable during prolonged storage, and exhibiting high impact resistance.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
The present invention addresses the problem of providing a chemical agent for suppressing the progression of Alzheimer-type dementia and a method for suppressing the progression of Alzheimer-type dementia. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of suppressing brain atrophy, and is useful as a prophylactic or therapeutic agent for brain atrophy. Thus, it is possible to prevent or treat brain atrophy observed in the aging process or in neurodegenerative diseases by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention addresses the problem of providing an agent and a method for suppressing the progression of tauopathy such as Alzheimer-type dementia. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of decreasing the level of phosphorylated tau protein and on decreasing the level of amyloid-ß protein in the brain parenchyma, and is useful as a prophylactic or therapeutic agent for tauopathy. Thus, it is possible to prevent or treat tauopathy by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
80.
AGENT FOR PREVENTING OR TREATING ALZHEIMER-TYPE DEMENTIA
The present invention addresses the problem of providing: an agent for suppressing the progression of Alzheimer-type dementia; and a method for suppressing the progression of Alzheimer-type dementia. According to the present invention, it is possible to effectively prevent or treat Alzheimer-type dementia by starting administration of a pharmaceutical composition containing 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof as an active ingredient to a patient within a certain period of time after that patient has been clinically diagnosed with Alzheimer-type dementia.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention addresses the problem of providing an agent and a method for suppressing the progression of tauopathy such as Alzheimer-type dementia. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of decreasing the level of phosphorylated tau protein and on decreasing the level of amyloid-β protein in the brain parenchyma, and is useful as a prophylactic or therapeutic agent for tauopathy. Thus, it is possible to prevent or treat tauopathy by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
82.
AGENT FOR PREVENTING OR TREATING SPINOCEREBELLAR ATAXIA
The present invention addresses the problem of providing a superior prophylactic or therapeutic agent for spinocerebellar ataxia. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of suppressing brain atrophy, in particular, cerebellar atrophy, and thus is useful as a prophylactic or therapeutic agent for spinocerebellar ataxia. Hence, it is possible to prevent or treat cerebellar atrophy observed in spinocerebellar ataxia by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
83.
AGENT FOR REDUCING AMOUNT OF AMYLOID .BETA. PROTEIN
The present invention addresses the problem of providing a pharmaceutical agent and a method for suppressing the progression of diseases such as Alzheimer-type dementia indicating an increase in the level of amyloid-ß protein in the brain. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of decreasing the level of amyloid-ß protein in the brain parenchyma, and hence is effective as an agent for decreasing the level of amyloid-ß protein in the brain. By administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof, it is possible to prevent or treat diseases in which an increase in the level of amyloid-ß protein in the brain occurs, such as Alzheimer-type dementia.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention addresses the problem of providing a chemical agent for suppressing the progression of Alzheimer-type dementia and a method for suppressing the progression of Alzheimer-type dementia. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of suppressing brain atrophy, and is useful as a prophylactic or therapeutic agent for brain atrophy. Thus, it is possible to prevent or treat brain atrophy observed in the aging process or in neurodegenerative diseases by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
85.
AGENT FOR PREVENTING OR TREATING SPINOCEREBELLAR ATAXIA
The present invention addresses the problem of providing a superior prophylactic or therapeutic agent for spinocerebellar ataxia. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of suppressing brain atrophy, in particular, cerebellar atrophy, and thus is useful as a prophylactic or therapeutic agent for spinocerebellar ataxia. Hence, it is possible to prevent or treat cerebellar atrophy observed in spinocerebellar ataxia by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention addresses the problem of providing a pharmaceutical agent and a method for suppressing the progression of diseases such as Alzheimer-type dementia indicating an increase in the level of amyloid-β protein in the brain. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of decreasing the level of amyloid-β protein in the brain parenchyma, and hence is effective as an agent for decreasing the level of amyloid-β protein in the brain. By administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof, it is possible to prevent or treat diseases in which an increase in the level of amyloid-β protein in the brain occurs, such as Alzheimer-type dementia.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
87.
Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof
Provided is a medicinal composition characterized by comprising an alkyl ether derivative represented by general formula [1]
3 represents an optionally protected hydroxyl group, etc.; and m and n are the same or different and represent an integer of 1 to 6] or a salt thereof. The medicinal composition according to the present invention is useful as a post nerve injury rehabilitation effect-enhancing agent.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61K 31/4422 - 1,4-Dihydropyridines, p. ex. nifédipine, nicardipine
A61P 31/20 - Antiviraux pour le traitement des virus ADN
C07D 409/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/443 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'oxygène comme hétéro-atome du cycle
A61K 31/4436 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
C07D 405/10 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 409/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
89.
PRODUCTION METHOD FOR CRYSTAL OF 5-CYCLOPROPYL-2-((1-(3-FLUOROBENZYL)-1H-INDOL-5-YL)-AMINO)NICOTINIC ACID
The present invention addresses the problem of providing a production method for crystals of 5-cyclopropyl-2-((1-(3-fluorobenzyl)-1H-indol-5-yl)amino)nicotinic acid. A compound represented by general formula [3] (wherein R1 represents an optionally substituted C1-3 alkyl group) is used as an intermediate in the production method provided by the present invention.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
Crystals of 5-cyclopropyl-2-((1-(3-fluorobenzyl)-1H-indol-5-yl)amino)nicotinic acid having diffraction peaks at diffraction angles (2θ) of 12.2±0.2, 17.2±0.2, 19.4±0.2, 24.1±0.2, and 27.1±0.2° or diffraction angles (2θ) of 12.9±0.2, 15.5±0.2, 21.2±0.2, 21.7±0.2, and 25.9±0.2° in powder x-ray diffraction have excellent stability, are easy to handle, and are useful as a drug substance of pharmaceuticals to be used in treatments such as the prevention or treatment of diseases involving keratinocyte hyperproliferation.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
91.
COMPOUND SERVING AS PRODRUG OF HYDROXAMIC ACID OR SALT OF SAID COMPOUND, FREEZE-DRIED MEDICINAL PREPARATION, LpxC INHIBITOR, AND ANTIBACTERIAL
The present invention addresses the problem of providing: a compound which shows potent antibacterial activity and excellent solubility in water or a salt of the compound; and a freeze-dried medicinal preparation, an LpxC inhibitor, and an antibacterial each containing the compound or salt. According to the present invention, a compound represented by general formula [1] or a salt thereof is provided. [In formula [1], R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 represents a hydrogen atom, etc.; and n is 0 or 1.]
The present invention addresses the problem of providing a pharmaceutical composition that contains a high concentration of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and masks the bitter taste thereof, and a method for producing the pharmaceutical composition. The present invention provides a pharmaceutical composition containing granules that have a core including 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and a binder, and have a polymer layer coated on the surface of the core, the granules having a roundness of 0.8 or higher, and the amount of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof contained in the granules being 30-90% by mass.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61K 9/32 - Revêtements organiques contenant des polymères synthétiques solides
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
Inventeur(s)
Makita Keiko
Saeki Kazunori
Tanaka Tadashi
Fujino Masataka
Natsume Tohru
Furuya Kentaro
Abrégé
The present invention addresses the problem of providing an antitumor agent that is exceptional as a treatment agent for the prevention and/or treatment of tumors involving bromodomains, and providing a bromodomain inhibitor that is useful as a treatment agent for diseases or conditions involving bromodomains. An antitumor agent and bromodomain inhibitor containing a compound represented by the general formula [in the formula, R1 represents a C1-6 alkyl group, etc.; R2 represents a hydrogen atom, etc.; R3 represents a halogen atom, etc.; Z1, Z2, and Z3 represent CH, etc.; X1 represents CONH, etc.; ring A represents a phenyl group, etc.; R4 represents a halogen atom, etc.; and m represents an integer of 0-5] have exceptional bromodomain inhibitory activity and are useful as treatment agents for the prevention and/or treatment of tumors involving bromodomains.
The present invention addresses the problem of providing a topical composition that brings about an enhanced skin permeability for 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof. The present invention provides a topical composition that contains: 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof; at least one solvent selected from the group consisting of alcohols, sulfoxides and amides; and an absorption enhancer.
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention addresses the problem of providing a solid pharmaceutical composition that suppresses the bitter taste characteristic of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and has excellent storage stability of the compound or salt thereof. The present invention provides a solid pharmaceutical composition including 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof, and a carboxylic acid having a solubility of 50 g/100 g H2O or lower in 25°C water, wherein when 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof is dissolved or suspended in 10 mmol/L KCl solution so as to reach 1 mg/mL or 8.96 mg/mL, the pH of the solution is 4.8 or lower.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
The present invention addresses the problem of providing a solid pharmaceutical composition that suppresses both the bitter taste and the bitter aftertaste of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof. The present invention provides a solid pharmaceutical composition that contains 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof, and a compound having at least one C8-18 hydrocarbon group and a sulfo group or a salt of this compound.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A sigma receptor-binding agent, which comprises an alkyl ether derivative represented by formula [1] or a salt thereof is provided.
3 represents an optionally protected hydroxyl group or the like; m and n, which are the same or different, each represent an integer of 1 to 6.
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
98.
Crystal forms of 6-bromo-3-hydroxy-2-pyrazinecarboxamide
The purpose of the present invention is to provide a method for producing 6-bromo-3-hydroxy-2-pyrazinecarboxamide in which the content ratio of impurities is reduced. This production method includes a step of obtaining 6-bromo-3-hydroxy-2-pyrazinecarboxamide crystal having diffraction angles expressed in degrees 2θ of 5.5, 20.1, 23.7, 26.7, 27.5, and 28.1° and/or diffraction angles expressed in degrees 2θ of 7.1, 21.4, 25.2, 25.7, 27.1, and 28.8° in powder X-ray diffraction.
Provided is a composition containing a buffer, the composition being used when a chelation targeting agent is labeled by 90Y, 153Sm, 165Dy, 165Er, 166Ho, or 177Lu. One or more buffers selected from benzoic acid, maleic acid, fumaric acid, succinic acid, and salts thereof are contained in a composition containing a chelation targeting agent.
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/50 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament
Provided is a transport device with which convenient thermal storage processing of the thermal storage material is possible even at a cell transport destination. This transport device is provided with a thermally insulated container that has a cylindrical shape and a bottom, a thermal storage material disposed along the inner circumferential surface of the thermally insulated container, and a temperature control unit that is detachably fitted on the thermally insulated container and is for performing thermal storage temperature control processing on the thermal storage material. The temperature control unit comprises a heat-transferring body for performing the thermal storage temperature control processing on the thermal storage material when the unit is fitted on the thermally insulated container, and a storage space formed inside the heat-transferring body for storing a stored object so that the object can be freely put in and taken out.
B65D 81/18 - Réceptacles, éléments d'emballage ou paquets pour contenus présentant des problèmes particuliers de stockage ou de transport ou adaptés pour servir à d'autres fins que l'emballage après avoir été vidés de leur contenu fournissant une ambiance spécifique pour le contenu, p. ex. température supérieure ou inférieure à la température ambiante
B65D 81/38 - Réceptacles, éléments d'emballage ou paquets pour contenus présentant des problèmes particuliers de stockage ou de transport ou adaptés pour servir à d'autres fins que l'emballage après avoir été vidés de leur contenu avec isolation thermique
B65D 85/50 - Réceptacles, éléments d'emballage ou paquets spécialement adaptés à des objets ou à des matériaux particuliers pour organismes vivants, objets ou matériaux sensibles aux changements d'ambiance ou de conditions atmosphériques, p. ex. pour animaux terrestres, oiseaux, poissons, plantes aquatiques, plantes non aquatiques, oignons de fleurs, fleurs coupées ou feuillage
F25D 3/00 - Dispositifs utilisant d'autres agents froidsDispositifs utilisant des récipients conservant le froid
F25D 11/00 - Dispositifs autonomes déplaçables associés à des machines frigorifiques, p. ex. réfrigérateurs ménagers
F25D 16/00 - Dispositifs utilisant une combinaison d'un procédé de refroidissement associé à des machines frigorifiques avec un procédé de refroidissement non associé à des machines frigorifiques
